Adult Dosing
Contrast use in imaging (MRI)
- 0.12 mL/kg (0.03 mmol/kg) IV (manual or power injection) over 30 seconds followed by 25-30 mL normal saline flush
- Note: Begin dynamic imaging immediately after injection and steady state imaging 5-7 minutes after drug administration
Pediatric Dosing
- Safety and effectiveness in pediatric patients (< 18 yrs) have not been established
See Supplemental Patient Information
- Hypersensitivity reactions, including anaphylactoid and/or anaphylactic reactions may result from administration of Gadofosveset
- Gadolinium-based contrast agents, may increase the risk for acute renal failure in patients with a history of renal insufficiency
- Gadolinium binds to blood albumin and use of a high-flux dialysis procedure is essential to optimized Gadolinium elimination in patients receiving chronic hemodialysis. The usefulness of hemodialysis in the prevention of NSF is unknown
- QTc prolongation has been reported following gadofosveset administration. Obtain baseline ECG and serum electrolyte levels in patients at risk for prolongation of QT/QTc interval
Cautions: Use cautiously in
- Renal impairment
- Prolonged QT syndrome
- Co-administration of drugs known to prolong Qt interval
- Hx of cardiac disease
- Electrolyte imbalances
- Hypokalemia
- Hypomagnesia
- Hypocalcemia
- Diabetes mellitus
- Autonomic neuropathy
Supplemental Patient Information
- Instruct patients to contact their physician if they develop signs or symptoms of NSF following gadofosveset trisodium administration
Pregnancy Category:C
Breastfeeding: Safety unknown; is excreted by < 1% (at doses up to 0.3 mmol/kg) in breast milk of lactating rats. Limited data indicates that 0.01-0.04% of the maternal dose is excreted in breast milk. Manufacturer recommends that gadofosveset use should be avoided unless diagnostic information is essential and not obtainable through other means.
